{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T18:01:44Z","timestamp":1774548104901,"version":"3.50.1"},"reference-count":9,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:p>\n                    Lung cancer is one of the most common causes of cancer-related deaths. Immune checkpoint inhibitors (ICIs) have improved the survival of patients with metastatic lung cancer. But, by activating the immune system, they can lead to immune-mediated adverse events. Here we report a case of metastatic lung adenocarcinoma presenting with right upper abdominal pain after initiation of pembrolizumab.\n                    <jats:sup>18<\/jats:sup>\n                    F-FDG PET\/CT highlighted the FDG avid thickening in the ICI-induced acalculous cholecystitis mimicking carcinoma gall bladder, which was confirmed on FNAC from the thickening and follow-up PET\/CT imaging.\n                  <\/jats:p>","DOI":"10.1097\/rlu.0000000000005905","type":"journal-article","created":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T01:00:30Z","timestamp":1751590830000},"page":"e42-e43","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Pembrolizumab-Induced Acalculous Cholecystitis Mimicking Gallbladder Carcinoma on 18F-FDG PET\/CT"],"prefix":"10.1097","volume":"51","author":[{"given":"Raza Abbas","family":"Mahdi","sequence":"first","affiliation":[{"name":"Nuclear Medicine and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Justin","family":"Raja","sequence":"additional","affiliation":[{"name":"Nuclear Medicine and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harmandeep","family":"Singh","sequence":"additional","affiliation":[{"name":"Nuclear Medicine and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bhagwant Rai","family":"Mittal","sequence":"additional","affiliation":[{"name":"Nuclear Medicine and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5098-5707","authenticated-orcid":false,"given":"Rajender","family":"Kumar","sequence":"additional","affiliation":[{"name":"Nuclear Medicine and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Navneet","family":"Singh","sequence":"additional","affiliation":[{"name":"Pulmonary Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2025,7,4]]},"reference":[{"key":"R1-20251210","doi-asserted-by":"crossref","first-page":"e858","DOI":"10.1097\/MEG.0000000000002280","article-title":"Immune-related cholangitis induced by immune checkpoint inhibitors: a systematic review of clinical features and management","volume":"33","author":"Pi","year":"2021","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"R2-20251210","doi-asserted-by":"crossref","first-page":"6493","DOI":"10.2147\/CMAR.S257188","article-title":"A Review about pembrolizumab in first-line treatment of advanced NSCLC: focus on KEYNOTE studies","volume":"12","author":"Qu","year":"2020","journal-title":"Cancer Manag Res"},{"key":"R3-20251210","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.4110\/in.2020.20.e9","article-title":"Clinical characteristics and treatment of immune-related adverse events of immune checkpoint inhibitors","volume":"20","author":"Choi","year":"2020","journal-title":"Immune Netw"},{"key":"R4-20251210","doi-asserted-by":"crossref","first-page":"691","DOI":"10.3390\/cancers15030691","article-title":"Immune-related adverse events of the gastrointestinal system","volume":"15","author":"Nicolaides","year":"2023","journal-title":"Cancers"},{"key":"R5-20251210","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s40425-019-0604-2","article-title":"Case series of cancer patients who developed cholecystitis related to immune checkpoint inhibitor treatment","volume":"7","author":"Abu-Sbeih","year":"2019","journal-title":"J Immunother Cancer"},{"key":"R6-20251210","doi-asserted-by":"crossref","first-page":"e34","DOI":"10.1016\/j.jtho.2017.10.007","article-title":"Late-onset cholecystitis with cholangitis after avelumab treatment in non\u2013small cell lung cancer","volume":"13","author":"Cho","year":"2018","journal-title":"J Thorac Oncol"},{"key":"R7-20251210","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1080\/1750743X.2024.2382670","article-title":"Successful replacement for recurrent nasopharyngeal carcinoma with cholecystitis induced by PD-1 antibody: a case report","volume":"16","author":"Liu","year":"2024","journal-title":"Immunotherapy"},{"key":"R8-20251210","doi-asserted-by":"crossref","first-page":"S1546","DOI":"10.14309\/01.ajg.0000958196.51273.d7","article-title":"What made the gallbladder angry? A case of ipilimumab and nivolumab induced acute cholecystitis","volume":"118","author":"Ravella","year":"2023","journal-title":"Am J Gastroenterol"},{"key":"R9-20251210","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1007\/s12094-022-02840-9","article-title":"Diagnostic impact of 18F-FDG PET\/CT imaging on the detection of immune-related adverse events in patients treated with immunotherapy","volume":"24","author":"Tatar","year":"2022","journal-title":"Clin Transl Oncol"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000005905","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T13:01:19Z","timestamp":1765371679000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000005905"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,4]]},"references-count":9,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000005905","relation":{},"ISSN":["0363-9762","1536-0229"],"issn-type":[{"value":"0363-9762","type":"print"},{"value":"1536-0229","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,4]]},"assertion":[{"value":"2025-01-14","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-14","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}